Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome
Validation of Enoxaparin Dose Adaptation in Patients With Moderate Renal Failure Hospitalized for an Acute Coronary Syndrome, the VALIDE Study
Sponsor: French Cardiology Society
Listed as NCT00412802, this PHASE4 trial focuses on Acute Coronary Syndrome and Renal Failure and remains completed. Sponsored by French Cardiology Society, it has been updated 6 times since 2006, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Dec 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- French Cardiology Society
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Besançon, France
- • Boulogne, France
- • Corbeil, France
- • Créteil, France
- • Lagny-sur-Marne, France
- • Paris, France
- • Toulouse, France